More than 300 regional experts gather in Cairo for Boehringer Ingelheim’s Forums to discuss latest advances in cardio-renal-metabolic care

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, hosted a dedicated event aimed at improving outcomes for patients living with cardiovascular, renal, and metabolic (CRM) diseases, such as chronic kidney disease, type 2 diabetes, and heart failure. The two-day event drew the participation of over 300 endocrinologists, nephrologists, cardiologists and primary care physicians from the Middle East and Africa,  and was held on October 11 and 12  at the Dusit Thani Lake View in Cairo, Egypt. This edition of the event combined two meetings, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting.

CRM diseases affect over one billion people globally¹ and pose a significant burden on both patients and healthcare systems. These interconnected conditions are the leading cause of death worldwide,¹ accounting for up to 20 million deaths annually.^2,3The intricate connection between the CRM systems signifies that disease in one system can often exert negative effects on others, increasing the risk of complications⁷. In light of this connection, extensive research has demonstrated that an integrated and multidisciplinary approach to treatment is essential for improving outcomes.⁷

The ‘CRM Summit’, held on the first day of the event, provided a forum for international and regional medical experts to discuss the urgency of early detection and diagnosis of interconnected CRM diseases. ‘MEDEX CRM’, the well-established medical education platform, which first launched in 2019, followed the next day. Participants delved into the latest data around CRM diseases and treatment guidelines, with this year’s meeting emphasizing the critical role of early diagnosis and intervention in chronic kidney disease. The event underscored the importance of having at-risk patients undergo both urine and blood tests to detect early signs of the serious renal disease. Both meetings included interactive case studies led by the international and regional faculties, mimicking real world clinical scenarios for attending doctors.

Derek O’Leary, Regional Managing Director at Boehringer Ingelheim for the India, Middle East, Turkey and Africa (IMETA) region, said, “At Boehringer Ingelheim, we are committed to innovating and improving the health of people affected by cardio-renal-metabolic diseases. Beyond developing innovative therapeutic solutions for patients, we prioritize building a collaborative network that brings the regional medical community together through hosting forums such as the ‘CRM Summit’ and ‘MEDEX CRM’. Dedicated to raising awareness about CRM diseases and discussing the latest treatment advances, this event supports us in fulfilling our company’s purpose of driving life forward and transforming lives for generations.”

Prof. Ibrahim Elebrashy, Professor of Internal Medicine, Diabetes and Endocrinology, Faculty of Medicine, Cairo University, FRCP Edinburgh, said, “As we gather here today, it is evident that the increasing prevalence of diabetes in the region demands more of our attention and collective action. With the number of people with diabetes in the Middle East and North Africa (MENA) region predicted to increase by 86% to reach 136 million by 2045⁸, and with our improved understanding of the interconnected nature of CRM diseases, it is crucial to embrace a mindset shift that recognizes this interconnectivity and treats those diseases accordingly.” Prof. Elebrashy added, “Adopting a holistic, multidisciplinary approach is key to protecting the health of the heart and kidneys in type 2 diabetes patients.”⁷

Prof. Merlin Thomas, Clinician Scientist and Program Leader in the Department of Diabetes at Monash University, said, “Forums like the ‘CRM Summit’ and ‘MEDEX CRM’ play an important role in raising awareness of the importance of early detection and intervention in chronic kidney disease and interconnected conditions. It is crucial to keep highlighting the importance of monitoring kidney health for patients at risk.  Two essential tests for this purpose should be considered – the urine albumin-creatinine ratio (uACR) test and the estimated glomerular filtration rate (eGFR) blood test.”⁹

Prof. Abdullah Alenezi, Consultant Cardiologist at Chest Diseases Hospital – Kuwait, added, “As it stands, heart failure affects over 64 million globally.¹⁰ In the Middle East, the average age of heart failure patients is at least ten years younger than it is in western counterparts.¹¹ This reflects the importance of such meetings that urge the healthcare community to stand united in the fight against heart failure and its interconnected conditions.”

As a leading biopharmaceutical company, Boehringer Ingelheim is committed to bringing value through innovation to patients living with CRM diseases. The company takes a long-term and holistic approach to improving the health of patients affected by these interconnected conditions. By driving life forward and leading the science that results in breakthrough therapies, Boehringer Ingelheim stays true to its purpose of improving the health of communities today, and for future generations.

–ENDS–

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. 

References:

1.  WHO. Non communicable diseases. Available at https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases Last Accessed 27/9/2024.

2.   Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204-1222.

3.   Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016;388(10053):1459-1544. 

4.   Norhammar A, Bodegard J, Eriksson JW, et al. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. Diabetes, Obesity and Metabolism. 2022;24(7):1277-1287. 

5.   Murphy A, Palafox B, Walli-Attaei M, et al. The household economic burden of non-communicable diseases in 18 countries. BMJ Global Health. 2020;5(2):e002040. 

6. Shah CH, Dave CV. Healthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019. Diabetology & Metabolic Syndrome. 2022;14(1):179. 

7.   Kadowaki T, Maegawa H, Watada H, et al. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. Diabetes Obes Metab. 2022;24(12):2283-2296. 

8.   IDF Diabetes Atlas. Available at https://diabetesatlas.org/ Last Accessed 27/9/2024.

9. National Kidney Foundation. Urine albumin-creatinine ratio (uACR). Available at https://www.kidney.org/kidney-topics/urine-albumin-creatinine-ratio-uacr#:~:text=The%20uACR%20is%20an%20important,(heart%20attack%20or%20stroke). Last Accessed 27/9/2024.

10.   Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology [published correction appears in Cardiovasc Res. 2023 Jun 13;119(6):1453. 

11.   Al-Shamiri MQ. Heart failure in the Middle East. Curr Cardiol Rev. 2013;9(2):174-178.